𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Proliferative response of CD4+ T cells and hepatitis B virus clearance in chronic hepatitis with or without hepatitis B e–minus hepatitis B virus mutants

✍ Scribed by Hanns F. Löhr; Wolfgang Weber; Jörg Schlaak; Bernd Goergen; Karl-Hermann Meyer Zum Büschenfelde; Guido Gerken


Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
920 KB
Volume
22
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis


To assess the significance of cell-mediated immunity, T cells were derived from the peripheral blood and liver tissue of hepatitis B virus (HBV)-infected patients and controls. The analysis of the 3H-thymidine-uptake in response to a panel of recombinant HBV antigens revealed that peripheral blood mononuclear cells (PBMC) of the 25 viremic patients with inflammatory active, chronic hepatitis B, 16 with wild-type and nine with Be-minus HBV mutant infection, showed stronger proliferative responses to HBc and HBe antigens than 16 asymptomatic nonviremic HBsAg carriers with normal aminotransferase levels (HBc: SI 19.3 t-3.9 vs. 13.0 2 3.2 vs. 8.0 ? 1.2; P < .01 and HBe: SI 16.6 5 4.0 vs. 10.7 ? 3.5 vs. 6.9 ? 1.5; P < .05). In 15 patients with acute self-limited hepatitis B, however, significantly stronger HBc antigen-specific T-cell responses were observed during HBV clearance and HBe/anti-HBe seroconversion, whereas in nine completely HBV-immunized patients only minor proliferative responses to HBV antigens were observed. Six HBe/ HBcAgand two HBeAg-specific CD4' T-cell lines could be expanded from liver tissue and peripheral blood of six viremic patients with chronic hepatitis B. Irrespectively of HBV mutations the HBV-specific activation of the T-cell lines was restricted by the presence of HLA-DR molecules and resulted in the release of Thl-like cytokine patterns. Follow-up of interferon (IFN) recipients showed simultaneous short-term increase of HBdHBe-


📜 SIMILAR VOLUMES


Efficacy of lamivudine in patients with
✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60

Low frequency of precore hepatitis B vir
✍ Marie Anne Loriot; Patrick Marcellin; Nathalie Talbodec; Véronique Guigonis; Mic 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 611 KB

The objective of this study was to evaluate the role of hepatitis B virus (HBV) precore mutations in patients with anti-me-positive chronic hepatitis B with or without previous known HBe antigen (HBeAg) viremic phase, and to assess the potential implication of precore mutants in HBeAg-negative react

Precore/core promoter mutations and geno
✍ Chun-Jen Liu; Jia-Horng Kao; Ming-Yang Lai; Pei-Jer Chen; Ding-Shinn Chen 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB 👁 2 views

## Abstract The association of precore stop codon mutation (A1896), dinucleotide mutation (T1762/A1764) in the basic core promoter of hepatitis B virus (HBV) genome, and genotype of HBV with fulminant or subfulminant hepatitis remains controversial. We studied HBV genotypes as well as mutations in

The phenotype of hepatitis B virus–speci
✍ J. Judy Chang; Alexander J. V. Thompson; Kumar Visvanathan; Stephen J. Kent; Pau 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 601 KB

## Hepatitis B virus (HBV)-specific T cells play a key role in clearance of the virus and in the pathogenesis of liver disease. Peripheral blood (n ‫؍‬ 25) and liver biopsies (n ‫؍‬ 19) were collected from individuals with chronic untreated HBV infection. Whole blood, cultured peripheral blood mon

Absence of hepatitis B virus precore mut
✍ Jianye Xu; David Brown; Tim Harrison; Yue Lin; Geoffrey Dusheiko 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 614 KB

Precore defective HBV mutants may gradually prevail because of immune selection and explain spontaneous seroconversion from HBeAg to anti-HBe in HBV carriers. We have analyzed whether the presence of precore HBV mutants is a determinant of responsiveness to interferon-a therapy. Fifteen carriers (ni